Anticancer Activity Studies of Ruthenium(II) Complex Toward Human Osteosarcoma HOS Cells

被引：5

作者：

Zhu, Jian-Wei ^{[1
]}

Liu, Si-Hong ^{[1
]}

Zhang, Gui-Qiang ^{[1
]}

Xu, Hui-Hua ^{[1
]}

Wang, Yu-Xuan ^{[1
]}

Wu, Yong ^{[2
]}

Liu, Ya-Min ^{[1
]}

Wang, Yan ^{[1
]}

Liang, Jun-Bo ^{[1
]}

Guo, Qi-Feng ^{[1
]}

机构：

[1] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Orthopaed, Guangzhou 510180, Guangdong, Peoples R China

[2] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Oncol, Guangzhou 510180, Guangdong, Peoples R China

来源：

JOURNAL OF MEMBRANE BIOLOGY | 2016年 / 249卷 / 04期

关键词：

Ruthenium(II) complex; Cytotoxicity in vitro and in vivo; Apoptosis; Reactive oxygen species; Cell cycle arrest; MITOCHONDRIAL PATHWAY; CYCLE ARREST; DNA-BINDING; IN-VITRO; NAMI-A; APOPTOSIS; CYTOTOXICITY; PROBES; OXYGEN;

D O I：

10.1007/s00232-016-9889-y

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A new Ru(II) complex [Ru(dmp)(2)(NMIP)](ClO4)(2) (dmp = 2,9-dimethyl-1,10-phenanthroline, NMIP = 2'-(2aEuro(3)-nitro-3aEuro(3),4aEuro(3)-methylenedioxyphenyl)imidazo[4',5'-f][1,10]-phenanthroline) was synthesized and characterized by elemental analysis, ESI-MS and H-1 NMR. The cytotoxic activity of the complex against MG-63, U2OS, HOS, and MC3T3-e1 cell lines was investigated by MTT method. The complex shows moderate cytotoxicity toward HOS (IC50 = 35.6 +/- 2.6 A mu M) and MC3T3-e1 (IC50 = 41.6 +/- 2.8 A mu M) cell lines. The morphological studies show that the complex can induce apoptosis in HOS cells and cause an increase of reactive oxygen species levels and a decrease in the mitochondrial membrane potential. The cell cycle distribution demonstrates that the complex inhibits the cell growth at S phase. Additionally, the antitumor activity in vivo reveals that the complex can induce a decrease in tumor weight.

引用

页码：483 / 492

页数：10

共 23 条

[1] Ruthenium-based chemotherapeutics: are they ready for prime time? [J].

Antonarakis, Emmanuel S. ;

Emadi, Ashkan .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) :1-9

[2]

Bergamo A, 1999, J PHARMACOL EXP THER, V289, P559

[3] Synthesis, acute toxicities, and antitumor effects of novel 9-substituted β-carboline derivatives [J].

Cao, RH ;

Chen, Q ;

Hou, XR ;

Chen, HS ;

Guan, HJ ;

Ma, Y ;

Peng, WL ;

Xu, AL .

BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (17) :4613-4623

[4] A ruthenium(II) β-carboline complex induced p53-mediated apoptosis in cancer cells [J].

Chen, Yu ;

Qin, Meng-Ying ;

Wang, Lei ;

Chao, Hui ;

Ji, Liang-Nian ;

Xu, An-Long .

BIOCHIMIE, 2013, 95 (11) :2050-2059

[5] SYNTHESIS AND STUDY OF MONONUCLEAR RUTHENIUM(II) COMPLEXES OF STERICALLY HINDERING DIIMINE CHELATES - IMPLICATIONS FOR THE CATALYTIC-OXIDATION OF WATER TO MOLECULAR-OXYGEN [J].

COLLIN, JP ;

SAUVAGE, JP .

INORGANIC CHEMISTRY, 1986, 25 (02) :135-141

[6] Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular "light switch" complexes [J].

Devi, C. Shobha ;

Kumar, D. Anil ;

Singh, Surya S. ;

Gabra, Nazar ;

Deepika, N. ;

Kumar, Y. Praveen ;

Satyanarayana, S. .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 64 :410-421

[7] Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells [J].

Emilia Juan, M. ;

Wenzel, Uwe ;

Daniel, Hannelore ;

Planas, Joana M. .

JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2008, 56 (12) :4813-4818

[8] Recent developments in the field of anticancer platinum complexes [J].

Galanski, Markus .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2006, 1 (02) :285-295

[9] Multinuclear ruthenium(II) complexes as anticancer agents [J].

Gorle, Anil K. ;

Ammit, Alaina J. ;

Wallace, Lynne ;

Keene, F. Richard ;

Collins, J. Grant .

NEW JOURNAL OF CHEMISTRY, 2014, 38 (09) :4049-4059

[10] Strained Ruthenium Complexes Are Potent Light-Activated Anticancer Agents [J].

Howerton, Brock S. ;

Heidary, David K. ;

Glazer, Edith C. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2012, 134 (20) :8324-8327

← 1 2 3 →